Human Papillomavirus (HPV) is a small, non-enveloped DNA virus with a circular genome that replicates in the nuclei of infected epithelial cells. The viral life cycle involves distinct phases, including viral entry, genome replication, and the production of viral particles. HPVs have evolved sophisticated mechanisms to evade host immune responses and establish persistent infections. High-risk HPV types, particularly HPV 16 and 18, are associated with oncogenic potential due to the expression of two key viral oncoproteins: E6 and E7. E6 promotes the degradation of the tumor suppressor protein p53, while E7 disrupts the function of the retinoblastoma protein (pRb), leading to uncontrolled cell proliferation. These interactions contribute to the development of HPV-associated cancers, including cervical and oropharyngeal cancers. Therapeutic approaches for HPV-related cancers include surgical interventions, radiation therapy, and antiviral drugs. Research into novel antiviral agents targeting specific steps of the viral life cycle is ongoing, aiming to inhibit viral replication and reduce the risk of cancer progression. Immunotherapies, such as therapeutic vaccines and immune checkpoint inhibitors, focus on enhancing the host immune response to clear HPV-infected cells. Understanding the molecular intricacies of HPV-host interactions is essential for developing targeted therapies and improving outcomes for individuals with HPV-associated diseases. Ongoing research aims to unravel the complexities of HPV pathogenesis, identify new therapeutic targets, and advance innovative approaches for the prevention and treatment of HPV infections and their associated cancers.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain